Viking Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9920 Pacific Heights Blvd Ste 500, San D...Phone Number
(858) 704-4660Website
www.vikingtherapeutics.comRevenue
$124.7 MillionStock Symbol
VKTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Viking Therapeutics
Viking Therapeutics, founded in 2012, is a clinical-stage biopharmaceutical company focused on developing novel, orally available therapies for metabolic and endocrine disorders. The company specializes in research and development of innovative therapeutics targeting metabolism to improve patient outcomes. Viking Therapeutics has multiple clinical programs in its portfolio, including treatments for lipid and metabolic disorders, X-linked adrenoleukodystrophy, and solutions for patients recovering from hip fractures. The company also has earlier-stage programs targeting metabolic diseases and anemia. Viking Therapeutics holds exclusive worldwide rights to a portfolio of therapeutic programs based on small molecules licensed from other pharmaceutical companies. The company is publicly traded and maintains operations across multiple locations in North America.Explore more
Viking Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Viking Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Viking Therapeutics has new funding data
Check out if Viking Therapeutics is spiking on competitors!
Product Launch: Get notified when Viking Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Viking Therapeutics had a recent Job posting/layoffs
Viking Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Viking Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Viking Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Viking Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Viking Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Viking Therapeutics
Compare insights from companies similar to Viking Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Viking Therapeutics financials insights
Gather financial insights about Viking Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$24M
Viking Therapeutics Tech Stack
A closer look at the technologies used by Viking Therapeutics
Most Recent Scoops
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Earnings
Viking Therapeutics has reported a cash position of over $600 million at the end of Q1, with sufficient funding to support top-line data readouts for its subcutaneous program anticipated in H2 2027, its oral Phase III program, and operations into the early portion of 2028.
Business Finance, Finance, Financing & Debt
Person-Based
Events
Person-Based
Events
Viking Therapeutics News & Media
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel...Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine...Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."
Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials.CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Viking Therapeutics
Sign Up For FreeTo access detailed company insights
Viking Therapeutics, founded in 2012, is a clinical-stage biopharmaceutical company focused on developing novel, orally available therapies for metabolic and endocrine disorders. The company specializes in research and development of innovative therapeutics targeting metabolism to improve patient outcomes. Viking Therapeutics has multiple clinical... Read More
